がん診断におけるAI市場(コンポーネント:ソフトウェアソリューションとサービス;癌タイプ:乳がん、前立腺がん、肺がん、大腸がん、子宮頸がん、その他) - 世界の産業分析、規模、シェア、成長、動向、予測、2023年~2031年AI in Cancer Diagnostics Market (Component: Software Solutions and Services; Cancer Type: Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 がん診断におけるAI市場 - レポートの範囲 TMR社のがん診断用AIの世界市場に関する調査レポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリーがん診断におけるAI市場 - レポートの範囲TMR社のがん診断用AIの世界市場に関する調査レポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。当レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界のがん診断におけるAI市場の収益を提供しています。また、2023年から2031年までの世界のがん診断におけるAI市場の複合年間成長率(CAGR %)も掲載しています。 本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、がん診断用AI市場を理解しました。 二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれる。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界のがん診断用AI市場の様々な属性を調査した。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界のがん診断におけるAI市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界のがん診断におけるAI市場への参入に関心のある企業にとっても貴重なツールとなります。 当レポートでは、世界のがん診断用AI市場の競争環境について掘り下げています。世界のがん診断用AI市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性の観点からプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートでプロファイリングされた世界のがん診断におけるAI市場におけるプレイヤーの属性である。 がん診断用AIの世界市場レポートが回答した主要な質問 - 予測期間中の全地域におけるがん診断用AIが生み出す売上高/収益は? - 世界のがん診断におけるAI市場における機会は何か? - 市場における主な促進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大する地域市場はどこか? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは? - 世界市場で事業を展開する各企業の市場ポジションは? がん診断におけるAI市場 - 調査目的と調査アプローチ 世界のがん診断におけるAI市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと販売業者、製品の承認に関する規制シナリオについて詳細に解説しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴える。また、過去と予測期間末の主要セグメントの市場シェアを比較することもできる。 本レポートでは、世界のがん診断におけるAI市場を製品、エンドユーザー、地域の観点から分析している。各基準における主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載している。このような貴重な洞察により、市場関係者は世界のがん診断におけるAI市場への投資について、情報に基づいたビジネス上の意思決定を行うことが可能になります。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global AI in Cancer Diagnostics Market 4. Market Overview 4.1. Introduction 4.1.1. Component Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global AI in Cancer Diagnostics Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Different Technique Overview of Machine Learning in Oncology 5.2. Technological Advancements 5.3. List of Major Software used as AI in Cancer Diagnostics 5.4. Regulatory Scenario by Region/Globally 5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact) 6. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Component 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Component, 2017-2031 6.3.1. Software Solutions 6.3.2. Services 6.4. Market Attractiveness Analysis, by Component 7. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Cancer Type 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Cancer Type, 2017-2031 7.3.1. Breast Cancer 7.3.2. Prostate Cancer 7.3.3. Lung Cancer 7.3.4. Colorectal Cancer 7.3.5. Cervical Cancer 7.3.6. Others 7.4. Market Attractiveness Analysis, by Cancer Type 8. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Application 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by Application, 2017-2031 8.3.1. Screening & Diagnosis 8.3.2. Tumor Identification 8.3.3. Monitoring 8.4. Market Attractiveness Analysis, by Application 9. Global AI in Cancer Diagnostics Market Analysis and Forecast, by End-user 9.1. Introduction & Definition 9.2. Key Findings/Developments 9.3. Market Value Forecast, by End-user, 2017-2031 9.3.1. Hospitals 9.3.2. Diagnostic Centers 9.3.3. Medical Research Institutes 9.3.4. Contract Research Organizations 9.4. Market Attractiveness Analysis, by End-user 10. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region, 2017-2031 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness Analysis, by Region 11. North America AI in Cancer Diagnostics Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Component, 2017-2031 11.2.1. Software Solutions 11.2.2. Services 11.3. Market Value Forecast, by Cancer Type, 2017-2031 11.3.1. Breast Cancer 11.3.2. Prostate Cancer 11.3.3. Lung Cancer 11.3.4. Colorectal Cancer 11.3.5. Cervical Cancer 11.3.6. Others 11.4. Market Value Forecast, by Application, 2017-2031 11.4.1. Screening & Diagnosis 11.4.2. Tumor Identification 11.4.3. Monitoring 11.5. Market Value Forecast, by End-user, 2017-2031 11.5.1. Hospitals 11.5.2. Diagnostic Centers 11.5.3. Medical Research Institutes 11.5.4. Contract Research Organizations 11.6. Market Value Forecast, by Country, 2017-2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Component 11.7.2. By Cancer Type 11.7.3. By Application 11.7.4. By End-user 11.7.5. By Country 12. Europe AI in Cancer Diagnostics Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Component, 2017-2031 12.2.1. Software Solutions 12.2.2. Services 12.3. Market Value Forecast, by Cancer Type, 2017-2031 12.3.1. Breast Cancer 12.3.2. Prostate Cancer 12.3.3. Lung Cancer 12.3.4. Colorectal Cancer 12.3.5. Cervical Cancer 12.3.6. Others 12.4. Market Value Forecast, by Application, 2017-2031 12.4.1. Screening & Diagnosis 12.4.2. Tumor Identification 12.4.3. Monitoring 12.5. Market Value Forecast, by End-user, 2017-2031 12.5.1. Hospitals 12.5.2. Diagnostic Centers 12.5.3. Medical Research Institutes 12.5.4. Contract Research Organizations 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Italy 12.6.5. Spain 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Component 12.7.2. By Cancer Type 12.7.3. By Application 12.7.4. By End-user 12.7.5. By Country/Sub-region 13. Asia Pacific AI in Cancer Diagnostics Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Component, 2017-2031 13.2.1. Software Solutions 13.2.2. Services 13.3. Market Value Forecast, by Cancer Type, 2017-2031 13.3.1. Breast Cancer 13.3.2. Prostate Cancer 13.3.3. Lung Cancer 13.3.4. Colorectal Cancer 13.3.5. Cervical Cancer 13.3.6. Others 13.4. Market Value Forecast, by Application, 2017-2031 13.4.1. Screening & Diagnosis 13.4.2. Tumor Identification 13.4.3. Monitoring 13.5. Market Value Forecast, by End-user, 2017-2031 13.5.1. Hospitals 13.5.2. Diagnostic Centers 13.5.3. Medical Research Institutes 13.5.4. Contract Research Organizations 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031 13.6.1. China 13.6.2. Japan 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Component 13.7.2. By Cancer Type 13.7.3. By Application 13.7.4. By End-user 13.7.5. By Country/Sub-region 14. Latin America AI in Cancer Diagnostics Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Component, 2017-2031 14.2.1. Software Solutions 14.2.2. Services 14.3. Market Value Forecast, by Cancer Type, 2017-2031 14.3.1. Breast Cancer 14.3.2. Prostate Cancer 14.3.3. Lung Cancer 14.3.4. Colorectal Cancer 14.3.5. Cervical Cancer 14.3.6. Others 14.4. Market Value Forecast, by Application, 2017-2031 14.4.1. Screening & Diagnosis 14.4.2. Tumor Identification 14.4.3. Monitoring 14.5. Market Value Forecast, by End-user, 2017-2031 14.5.1. Hospitals 14.5.2. Diagnostic Centers 14.5.3. Medical Research Institutes 14.5.4. Contract Research Organizations 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Component 14.7.2. By Cancer Type 14.7.3. By Application 14.7.4. By End-user 14.7.5. By Country/Sub-region 15. Middle East & Africa AI in Cancer Diagnostics Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Component, 2017-2031 15.2.1. Software Solutions 15.2.2. Services 15.3. Market Value Forecast, by Cancer Type, 2017-2031 15.3.1. Breast Cancer 15.3.2. Prostate Cancer 15.3.3. Lung Cancer 15.3.4. Colorectal Cancer 15.3.5. Cervical Cancer 15.3.6. Others 15.4. Market Value Forecast, by Application, 2017-2031 15.4.1. Screening & Diagnosis 15.4.2. Tumor Identification 15.4.3. Monitoring 15.5. Market Value Forecast, by End-user, 2017-2031 15.5.1. Hospitals 15.5.2. Diagnostic Centers 15.5.3. Medical Research Institutes 15.5.4. Contract Research Organizations 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Component 15.7.2. By Cancer Type 15.7.3. By Application 15.7.4. By End-user 15.7.5. By Country/Sub-region 16. Competition Landscape 16.1. Market Player - Competition Matrix, by tier and size of companies 16.2. Market Share Analysis, by Company, 2022 16.3. Company Profiles 16.3.1. Ibex Medical Analytics 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. EarlySign 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Cancer Center.ai 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. Microsoft 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Flatiron 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. Path AI 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. Therapixel 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Tempus 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Paige AI, Inc. 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.9.2. Product Portfolio 16.3.9.3. Financial Overview 16.3.9.4. SWOT Analysis 16.3.9.5. Strategic Overview 16.3.10. Kheiron Medical Technologies Limited 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.10.2. Product Portfolio 16.3.10.3. Financial Overview 16.3.10.4. SWOT Analysis 16.3.10.5. Strategic Overview 16.3.11. SkinVision 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.11.2. Product Portfolio 16.3.11.3. Financial Overview 16.3.11.4. SWOT Analysis 16.3.11.5. Strategic Overview 16.3.12. Freenome 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.12.2. Product Portfolio 16.3.12.3. Financial Overview 16.3.12.4. SWOT Analysis 16.3.12.5. Strategic Overview 16.3.13. Whiterabbit.ai 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.13.2. Product Portfolio 16.3.13.3. Financial Overview 16.3.13.4. SWOT Analysis 16.3.13.5. Strategic Overview 16.3.14. Mindpeak GmbH 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.14.2. Product Portfolio 16.3.14.3. Financial Overview 16.3.14.4. SWOT Analysis 16.3.14.5. Strategic Overview
SummaryAI in Cancer Diagnostics Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global AI in Cancer Diagnostics Market 4. Market Overview 4.1. Introduction 4.1.1. Component Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global AI in Cancer Diagnostics Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Different Technique Overview of Machine Learning in Oncology 5.2. Technological Advancements 5.3. List of Major Software used as AI in Cancer Diagnostics 5.4. Regulatory Scenario by Region/Globally 5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact) 6. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Component 6.1. Introduction & Definition 6.2. Key Findings/Developments 6.3. Market Value Forecast, by Component, 2017-2031 6.3.1. Software Solutions 6.3.2. Services 6.4. Market Attractiveness Analysis, by Component 7. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Cancer Type 7.1. Introduction & Definition 7.2. Key Findings/Developments 7.3. Market Value Forecast, by Cancer Type, 2017-2031 7.3.1. Breast Cancer 7.3.2. Prostate Cancer 7.3.3. Lung Cancer 7.3.4. Colorectal Cancer 7.3.5. Cervical Cancer 7.3.6. Others 7.4. Market Attractiveness Analysis, by Cancer Type 8. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Application 8.1. Introduction & Definition 8.2. Key Findings/Developments 8.3. Market Value Forecast, by Application, 2017-2031 8.3.1. Screening & Diagnosis 8.3.2. Tumor Identification 8.3.3. Monitoring 8.4. Market Attractiveness Analysis, by Application 9. Global AI in Cancer Diagnostics Market Analysis and Forecast, by End-user 9.1. Introduction & Definition 9.2. Key Findings/Developments 9.3. Market Value Forecast, by End-user, 2017-2031 9.3.1. Hospitals 9.3.2. Diagnostic Centers 9.3.3. Medical Research Institutes 9.3.4. Contract Research Organizations 9.4. Market Attractiveness Analysis, by End-user 10. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region, 2017-2031 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness Analysis, by Region 11. North America AI in Cancer Diagnostics Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Component, 2017-2031 11.2.1. Software Solutions 11.2.2. Services 11.3. Market Value Forecast, by Cancer Type, 2017-2031 11.3.1. Breast Cancer 11.3.2. Prostate Cancer 11.3.3. Lung Cancer 11.3.4. Colorectal Cancer 11.3.5. Cervical Cancer 11.3.6. Others 11.4. Market Value Forecast, by Application, 2017-2031 11.4.1. Screening & Diagnosis 11.4.2. Tumor Identification 11.4.3. Monitoring 11.5. Market Value Forecast, by End-user, 2017-2031 11.5.1. Hospitals 11.5.2. Diagnostic Centers 11.5.3. Medical Research Institutes 11.5.4. Contract Research Organizations 11.6. Market Value Forecast, by Country, 2017-2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Component 11.7.2. By Cancer Type 11.7.3. By Application 11.7.4. By End-user 11.7.5. By Country 12. Europe AI in Cancer Diagnostics Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Component, 2017-2031 12.2.1. Software Solutions 12.2.2. Services 12.3. Market Value Forecast, by Cancer Type, 2017-2031 12.3.1. Breast Cancer 12.3.2. Prostate Cancer 12.3.3. Lung Cancer 12.3.4. Colorectal Cancer 12.3.5. Cervical Cancer 12.3.6. Others 12.4. Market Value Forecast, by Application, 2017-2031 12.4.1. Screening & Diagnosis 12.4.2. Tumor Identification 12.4.3. Monitoring 12.5. Market Value Forecast, by End-user, 2017-2031 12.5.1. Hospitals 12.5.2. Diagnostic Centers 12.5.3. Medical Research Institutes 12.5.4. Contract Research Organizations 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Italy 12.6.5. Spain 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Component 12.7.2. By Cancer Type 12.7.3. By Application 12.7.4. By End-user 12.7.5. By Country/Sub-region 13. Asia Pacific AI in Cancer Diagnostics Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Component, 2017-2031 13.2.1. Software Solutions 13.2.2. Services 13.3. Market Value Forecast, by Cancer Type, 2017-2031 13.3.1. Breast Cancer 13.3.2. Prostate Cancer 13.3.3. Lung Cancer 13.3.4. Colorectal Cancer 13.3.5. Cervical Cancer 13.3.6. Others 13.4. Market Value Forecast, by Application, 2017-2031 13.4.1. Screening & Diagnosis 13.4.2. Tumor Identification 13.4.3. Monitoring 13.5. Market Value Forecast, by End-user, 2017-2031 13.5.1. Hospitals 13.5.2. Diagnostic Centers 13.5.3. Medical Research Institutes 13.5.4. Contract Research Organizations 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031 13.6.1. China 13.6.2. Japan 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Component 13.7.2. By Cancer Type 13.7.3. By Application 13.7.4. By End-user 13.7.5. By Country/Sub-region 14. Latin America AI in Cancer Diagnostics Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Component, 2017-2031 14.2.1. Software Solutions 14.2.2. Services 14.3. Market Value Forecast, by Cancer Type, 2017-2031 14.3.1. Breast Cancer 14.3.2. Prostate Cancer 14.3.3. Lung Cancer 14.3.4. Colorectal Cancer 14.3.5. Cervical Cancer 14.3.6. Others 14.4. Market Value Forecast, by Application, 2017-2031 14.4.1. Screening & Diagnosis 14.4.2. Tumor Identification 14.4.3. Monitoring 14.5. Market Value Forecast, by End-user, 2017-2031 14.5.1. Hospitals 14.5.2. Diagnostic Centers 14.5.3. Medical Research Institutes 14.5.4. Contract Research Organizations 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Component 14.7.2. By Cancer Type 14.7.3. By Application 14.7.4. By End-user 14.7.5. By Country/Sub-region 15. Middle East & Africa AI in Cancer Diagnostics Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Component, 2017-2031 15.2.1. Software Solutions 15.2.2. Services 15.3. Market Value Forecast, by Cancer Type, 2017-2031 15.3.1. Breast Cancer 15.3.2. Prostate Cancer 15.3.3. Lung Cancer 15.3.4. Colorectal Cancer 15.3.5. Cervical Cancer 15.3.6. Others 15.4. Market Value Forecast, by Application, 2017-2031 15.4.1. Screening & Diagnosis 15.4.2. Tumor Identification 15.4.3. Monitoring 15.5. Market Value Forecast, by End-user, 2017-2031 15.5.1. Hospitals 15.5.2. Diagnostic Centers 15.5.3. Medical Research Institutes 15.5.4. Contract Research Organizations 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Component 15.7.2. By Cancer Type 15.7.3. By Application 15.7.4. By End-user 15.7.5. By Country/Sub-region 16. Competition Landscape 16.1. Market Player - Competition Matrix, by tier and size of companies 16.2. Market Share Analysis, by Company, 2022 16.3. Company Profiles 16.3.1. Ibex Medical Analytics 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. EarlySign 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Cancer Center.ai 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. Microsoft 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Flatiron 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. Path AI 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. Therapixel 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Tempus 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Paige AI, Inc. 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.9.2. Product Portfolio 16.3.9.3. Financial Overview 16.3.9.4. SWOT Analysis 16.3.9.5. Strategic Overview 16.3.10. Kheiron Medical Technologies Limited 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.10.2. Product Portfolio 16.3.10.3. Financial Overview 16.3.10.4. SWOT Analysis 16.3.10.5. Strategic Overview 16.3.11. SkinVision 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.11.2. Product Portfolio 16.3.11.3. Financial Overview 16.3.11.4. SWOT Analysis 16.3.11.5. Strategic Overview 16.3.12. Freenome 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.12.2. Product Portfolio 16.3.12.3. Financial Overview 16.3.12.4. SWOT Analysis 16.3.12.5. Strategic Overview 16.3.13. Whiterabbit.ai 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.13.2. Product Portfolio 16.3.13.3. Financial Overview 16.3.13.4. SWOT Analysis 16.3.13.5. Strategic Overview 16.3.14. Mindpeak GmbH 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.14.2. Product Portfolio 16.3.14.3. Financial Overview 16.3.14.4. SWOT Analysis 16.3.14.5. Strategic Overview
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Transparency Market Research社の医療分野での最新刊レポート
本レポートと同じKEY WORD(analysis size)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |